OnGuard® 2
Closed System Transfer Device

Protecting healthcare workers at every connection point

B|BRAUN
SHARING EXPERTISE

Advancing Protection for Nurses Handling Hazardous Drugs

Every day, oncology nurses working on the front line of patient care face potential exposure to hazardous drugs. Administration of medication is where many of the highest-risk moments occur. OnGuard® 2 is a closed system transfer device (CSTD) designed to help protect nurses from exposure to hazardous drugs.

Proven Protection

Tested for vapor containment using real chemotherapy drugs, the OnGuard 2 CSTD helps protect you, so you can stay focused on delivering safe, high-quality patient care.

Tested with:

- **5-Fluorouracil**
- **Cyclophosphamide**
- **Doxorubicin-HCl**

Engineered for Safety

OnGuard 2 CSTD uses a drug-binding matrix as a mechanical barrier to help reduce hazardous drug exposure and support a sterile, user-friendly preparation process, so you can work with confidence.

Product Features:

- Audible click-to-lock confirms a secure connection
- Membrane-to-membrane design supports dry disconnection[1]
- Non-removable syringe adaptor for added safety
- Materials optimized for compatibility with hazardous drugs[2]
- Designed to minimize residual volume, including a 60% reduction with the Luer lock adaptor[3]

NOT MADE WITH DEHP OR PVC

Components

Syringe Adaptor Lock

Luer Lock Adaptor

Spike Port Adaptor

Designed for ease of use and protection, OnGuard 2 CSTD helps safeguard against:[4,5]

- Harmful inhalation
- Skin contact
- Unintentional hand-to-mouth ingestion
- Needlestick and sharps injury

1. Levin G, Sessink PJ. Validation of chemotherapy drug vapor containment of an air cleaning closed-system drug transfer device. J Oncol Pharm Pract 2022;28(7):1508-1515. doi:10.1177/10781552211030682
2. Compatibility with Known Hazardous Drugs.
3. Chemfort System Residual Volume. Simplivia. 2022:1-3
4. NIOSH Alert. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. Available at: https://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf
5. Vyas N, Yiannakis D, Turner A, et al. Occupational exposure to anti-cancer drugs: a review of effects of new technology. J Oncol Pharm Pract. 2014 Aug;20(4):278-287. doi:10.1177/1078155213498630. PMID:23975555

B. Braun Medical Inc. | Bethlehem, PA | 800-227-2862 | bbraunusa.com

OnGuard 2 is manufactured by Simplivia Healthcare Ltd. and distributed by B. Braun Medical Inc.
Rx only. Confidential and Proprietary. ©2026 B. Braun Medical Inc. All rights reserved. 26-0352_09/26
IVX62